AI-Powered Autism Screening Tools in 2026: What They Can and Can’t Do

AI-powered autism screening tools in 2026 - 101Autism guide

By Dror Arbel, a parent, not a clinician. Updated November 2026. This page is general information, not medical advice.

Quick answer: As of November 2026 the FDA has authorized a small group of AI-based diagnosis aids for young children: Cognoa’s Canvas Dx, Earlitec’s EarliPoint eye-tracking system and, most recently, Argus Cognitive’s Neurora (October 2026). They are prescribed and used by clinicians, not by parents at home, and they support a diagnosis rather than replace one. Free online quizzes, including the ones on this site, are questionnaires, not AI, and none of them can diagnose autism.

Contents

What Counts as an AI Autism Screening Tool?

Traditional screening uses validated questionnaires such as the M-CHAT-R/F for toddlers or the AQ-10 for adults. A person answers fixed questions and a simple score is added up. AI tools are different: a trained machine-learning model combines several inputs, for example a caregiver questionnaire, short home videos, eye-tracking data or a clinician’s checklist, and produces an output.

Two terms matter. A screening tool flags who should be evaluated further. A diagnosis aid helps a qualified clinician decide whether a child meets criteria for autism. The FDA-authorized devices below are diagnosis aids for clinicians. A formal diagnosis still comes from a clinician applying DSM-5-TR criteria.

FDA-Authorized AI Autism Tools in 2026

The FDA created a device category called “Pediatric Autism Spectrum Disorder Diagnosis Aid” (product code QPF, regulation 21 CFR 882.1491) when it authorized Cognoa’s first device in 2021. Devices listed under that code as of November 2026:

DeviceCompanyHow it worksFDA history
Canvas Dx (originally Cognoa ASD Diagnosis Aid)CognoaA caregiver questionnaire, short videos of the child reviewed by trained analysts, and a clinician questionnaire are combined by a machine-learning model. It can return positive, negative or indeterminate.De Novo authorization June 2021 (ages 18 to 72 months); updated 510(k) clearance April 2025
EarliPointEarlitec DiagnosticsMeasures where a child looks while watching short videos of social scenes (eye-tracking) and compares the pattern with reference data.First cleared June 2022 (ages 16 to 30 months); further clearances 2023, 2025 and March 2026
NeuroraArgus CognitiveAI-based diagnosis aid in the same FDA category; details of the method and age range are in its FDA record.510(k) clearance October 2, 2026 (K260064)

FDA clearance means the device met the agency’s requirements for its stated use. It does not mean the tool is right for every child, and insurance coverage varies. Ask your pediatrician or developmental clinic whether they use one of these tools.

How Accurate Are AI Autism Tools?

  • Canvas Dx: In the pivotal study (Megerian et al., 2022, npj Digital Medicine; 425 children aged 18 to 72 months at 14 US sites), the device gave a definite answer for only about a third of children and returned “indeterminate” for the rest. When it did give an answer, it was usually right (positive predictive value about 81%, negative predictive value about 98%). An indeterminate result means the child still needs a standard evaluation.
  • EarliPoint: In two validation studies published in JAMA (Jones et al., 2023; children 16 to 30 months), eye-tracking results agreed well with expert diagnosis. In the second study sensitivity was about 71% and specificity about 81%, so some autistic children were missed and some non-autistic children were flagged.
  • Research tools: Many studies report very high accuracy for AI models using videos, voice, EEG or retinal images, but most are small, run in research settings and have not been tested in everyday clinics. Treat headline numbers like “95% accurate” with caution until a tool is independently validated.

Bottom line: the best current AI tools may help some children get a diagnosis sooner from a primary care clinician, but they do not work for every child and they are not a home test.

Consumer Apps and Online Quizzes

Many apps and websites now call themselves “AI autism tests.” Unless a product is listed in the FDA database for its intended use, it has not been reviewed as a diagnostic device. Before using one, check who made it, what data it collects (especially videos of your child), whether it publishes peer-reviewed results, and whether it pushes paid services.

The free tools on 101Autism are standard questionnaires, not AI. They can help you decide whether to talk to a professional:

Limits and Ethical Concerns

  • Bias: Models trained mostly on one group (for example boys, English speakers or families who can reach research centers) may work less well for girls, adults, minority groups or children with co-occurring conditions.
  • Indeterminate results: A tool that answers only when it is confident can look very accurate while leaving many children without an answer.
  • Privacy: Videos and eye-tracking data of children are sensitive. Ask how long data is kept and who can see it.
  • Access: Devices must be prescribed and may not be covered by insurance.
  • Not a replacement for support: A faster diagnosis matters only if families can then reach early intervention, speech, OT and school services.

What Parents and Adults Can Do Now

  1. If you have concerns about a young child, raise them with your pediatrician now. The AAP recommends autism screening at the 18- and 24-month visits, and you do not need a diagnosis to request a free Early Intervention evaluation (birth to 3) in the US.
  2. Ask whether your clinic uses an FDA-authorized diagnosis aid or can refer you for a standard evaluation, such as the ADOS-2.
  3. Adults can start with a validated questionnaire and then look for an assessor: where to get tested as an adult.
  4. Write down examples of what you notice (videos help) to bring to the appointment.

Preparing for an autism assessment?

The Pre-Assessment Checklist helps you organize observations, questions and paperwork before the appointment.

See the Pre-Assessment Checklist (PDF)

From 101Autism.com. An organizing tool, not medical advice.

Frequently Asked Questions

Can AI diagnose autism?

No AI tool diagnoses autism on its own. FDA-authorized devices such as Canvas Dx, EarliPoint and Neurora are diagnosis aids that a clinician uses as part of an evaluation.

Is there an FDA-approved AI autism test I can use at home?

No. The authorized devices are prescription tools used by clinicians. Some involve steps at home, such as filming short videos, but the result goes to the clinician.

How accurate is Canvas Dx?

In its pivotal study it gave a definite result for about a third of children aged 18 to 72 months; when it did, it was usually correct (PPV about 81%, NPV about 98%). Other children received an indeterminate result and needed a standard evaluation.

What ages are AI autism tools for?

The FDA-authorized devices are for young children: Canvas Dx was first authorized for 18 to 72 months and EarliPoint for 16 to 30 months. There is no FDA-authorized AI diagnostic tool for adults.

Are online AI autism quizzes reliable?

Most are not validated. A validated questionnaire such as the M-CHAT-R/F or AQ-10 is a better starting point, and any result should be discussed with a professional.

Sources

  • US FDA. Premarket notification K260064, Neurora (Argus Cognitive), decision October 2, 2026; product code QPF, Pediatric Autism Spectrum Disorder Diagnosis Aid, 21 CFR 882.1491.
  • US FDA. De Novo DEN200069, Cognoa ASD Diagnosis Aid (2021); 510(k) K243558, Canvas Dx (2025).
  • US FDA. 510(k) K213882, EarliPoint System (2022); K230337 (2023); K243891 (2025); K253442 (2026).
  • Megerian, J. T., et al. (2022). Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disorder. npj Digital Medicine, 5, 57.
  • Jones, W., et al. (2023). Eye-tracking-based measurement of social visual engagement compared with expert clinical diagnosis of autism. JAMA, 330(9), 854-865.
  • Hyman, S. L., Levy, S. E., Myers, S. M., & AAP Council on Children with Disabilities (2020). Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics, 145(1).
  • CDC. Screening and Diagnosis of Autism Spectrum Disorder.

Discover more from Living with Autism

Subscribe to get the latest posts sent to your email.

Dror Arbel

I'm Dror Arbel, Saar's parent and the founder of 101Autism.com. Saar is an autistic teenager who loves football, cycling and music, plays the piano and paints. Loud sounds can overwhelm him and sudden changes unsettle him, so much of what I write about comes from real life at home and at school. I started 101Autism to share our family's journey and to turn what we have learned about testing, school and daily life into clear, practical guides. I am a parent, not a clinician: I link to research and official sources, and nothing on this site replaces advice from a qualified professional.

You may also like...

1 Response

  1. 2025/10/28

    […] outcomes. However, traditional screening methods often delay diagnosis until after age six. Artificial intelligence is revolutionizing autism screening. It combines video analysis, voice […]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from Living with Autism

Subscribe now to keep reading and get access to the full archive.

Continue reading